The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer’s disease

Author： Thompson Sarah   Lanctôt Krista L   Herrmann Nathan  

Publisher： Informa Healthcare

ISSN： 1474-0338

Source： Expert Opinion on Drug Safety, Vol.3, Iss.5, 2004-09, pp. : 425-440

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Long-Term Cholinesterase Inhibitor Treatment of Alzheimer’s Disease

By Peter Johannsen  

CNS Drugs, Vol. 18, Iss. 12, 2004-01 ,pp. : 757-768

Adis International

Access to resources Recommend Favorite

Pharmacoeconomics of Cholinesterase Inhibitors in the Treatment of Alzheimer’s Disease

By Jönsson L.  

PharmacoEconomics, Vol. 21, Iss. 14, 2003-01 ,pp. : 1025-1037

Adis International

Access to resources Recommend Favorite

Selectivity of Cholinesterase Inhibition: Clinical Implications for the Treatment of Alzheimer’s Disease

By Weinstock M.  

CNS Drugs, Vol. 12, Iss. 4, 1999-10 ,pp. : 307-323

Adis International

Access to resources Recommend Favorite

The Role of Bridging Studies in the Development of Cholinesterase Inhibitors for Alzheimer’s Disease

By Cutler N.R.   Sramek J.J.  

CNS Drugs, Vol. 10, Iss. 5, 1998-11 ,pp. : 355-364

Adis International

Access to resources Recommend Favorite

Novel cholinesterase inhibitors as future effective drugs for the treatment of Alzheimer’s disease

By Martinez Ana   Castro Ana  

Expert Opinion on Investigational Drugs, Vol. 15, Iss. 1, 2006-01 ,pp. : 1-12

Informa Healthcare

Access to resources Recommend Favorite